ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RLMD vs AVTX // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

Relmada Therapeutics Inc. (NASDAQ) VS. Avalo Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: RLMD 2 — AVTX 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RLMD VS. AVTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RLMD AVTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -12.48% -12.90% +0.42 RLMD /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -65.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.66 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 2/9 -1.00 AVTX /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 52.7 24.4 +28.30 RLMD /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $381.9M $384.5M -$2.6M AVTX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RLMD REV AVTX REV RLMD GROSS % AVTX GROSS % RLMD FCF AVTX FCF
FY 2025 $165.5M $59.0K — — -$45.8M -$51.5M
FY 2024 $234.9M $441.0K — — -$51.8M -$49.1M
FY 2023 — $1.9M — — — -$30.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RLMD // BETA —
AVTX // BETA —